Cover Image
Market Research Report

North America Orthobiologics Market Forecast 2019-2027

Published by Inkwood Research Product code 492791
Published Content info 82 Pages
Delivery time: 2-3 business days
Price
Back to Top
North America Orthobiologics Market Forecast 2019-2027
Published: March 20, 2019 Content info: 82 Pages
Description

KEY INSIGHTS

North America orthobiologics market finds its application in spinal fusion, trauma repair, reconstructive surgery, tendon and ligament repair, and others. The orthobiologics market in North America is growing at a CAGR of 5.10% (in million $) owing due to the growth in geriatric population coupled with the rise in disposable income paving the way for the market in this region.

MARKET INSIGHTS

The alertness about orthobiologics is a lashing force for surgeons to switch from mechanical implants to biological implants. The market's increase since 2012 is due to increased research and rising demand for the products due to their benefits.

Also, the United States orthobiologics market has the largest share in North America, and it's expected to continue growing. The Canadian region will also have growth driven by increasing research investments thereby helping the market to develop in this region.

However, the high costs of spinal and other orthopedic surgeries are one of the major factors which are hampering the growth of the market in forecast period 2019-2027.

COMPETITIVE ANALYSIS

Integra Lifesciences Holding Corporation, Sanofi, Stryker Corporation, Zimmer Biomet Inc., Nuvasive Inc., Depuy Inc. (Acquired by Johnson and Johnson), Medtronic Inc., Smith & Nephew Plc, RTI Surgical, Allosource, Exactech Inc., Amedica Corporation, Baxter International Inc., AAP Implantate AG and Conmed Corporation are the companies mentioned in the report.

Table of Contents
Product Code: 5131

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. HOSPITALS ARE THE LARGEST REVENUE GENERATING END-USER
    • 3.2.2. SPINAL FUSION IS THE FASTEST GROWING APPLICATION
    • 3.2.3. VISCOSUPPLEMENTATION HOLDS THE LARGEST MARKET SHARE IN TERMS OF PRODUCTS

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. SURGING DEMAND FOR SPINAL FUSION SURGERIES
    • 4.2.2. INCREASING GERIATRIC POPULATION
    • 4.2.3. INCREASE ORTHOPAEDIC RELATED DISEASES DUE TO LIFESTYLE CHOICES
    • 4.2.4. TECHNOLOGICAL ADVANCEMENT
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. STRINGENT GOVERNMENT POLICIES
    • 4.3.2. POST-SURGERY COMPLICATIONS
    • 4.3.3. HIGH COST OF ORTHOPEDICS IMPLANTS
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. INCREASED UTILIZATION OF BONE REGENERATION TECHNOLOGY
    • 4.4.2. GROWING DISPOSABLE INCOME
    • 4.4.3. EXPANSION OF COST EFFECTIVE MEDICAL PRODUCTS
    • 4.4.4. HUGE MARKET OPPORTUNITIES IN DEVELOPING COUNTRIES
  • 4.5. MARKET CHALLENGES
    • 4.5.1. HIGH COST OF SPINAL FUSION SURGERY
    • 4.5.2. POOR PERFORMANCE OF BONE GRAFT SUBSTITUTE

5. MARKET BY END-USER

  • 5.1. HOSPITALS
  • 5.2. ORTHOPEDIC CLINICS

6. MARKET BY PRODUCTS

  • 6.1. DEMINERALIZED BONE MATRIX (DBM)
  • 6.2. ALLOGRAFT
  • 6.3. BONE MORPHOGENETIC PROTEIN (BMP)
  • 6.4. VISCOSUPPLEMENTATION
  • 6.5. SYNTHETIC BONE SUBSTITUTES
  • 6.6. STEM CELL THERAPY
  • 6.7. OTHER PRODUCTS

7. MARKET BY APPLICATION

  • 7.1. SPINAL FUSION
  • 7.2. TRAUMA REPAIR
  • 7.3. RECONSTRUCTIVE SURGERY
  • 7.4. TENDON AND LIGAMENT
  • 7.5. OTHER APPLICATIONS

8. KEY ANALYTICS

  • 8.1. PORTER'S FIVE FORCE MODEL
    • 8.1.1. THREAT OF NEW ENTRANTS
    • 8.1.2. THREAT OF SUBSTITUTE
    • 8.1.3. BARGAINING POWER OF BUYER
    • 8.1.4. BARGAINING POWER OF SUPPLIER
    • 8.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 8.2. PESTEL ANALYSIS
  • 8.3. PATENT ANALYSIS
  • 8.4. KEY BUYING CRITERIA
  • 8.5. VALUE CHAIN ANALYSIS
  • 8.6. OPPORTUNITY MATRIX

9. GEOGRAPHICAL ANALYSIS

  • 9.1. NORTH AMERICA
    • 9.1.1. THE UNITED STATES
    • 9.1.2. CANADA

10. COMPETITIVE LANDSCAPE

  • 10.1. MARKET SHARE ANALYSIS
  • 10.2. COMPANY PROFILES
    • 10.2.1. AAP IMPLANTATE AG
      • 10.2.1.1. COMPANY OVERVIEW
      • 10.2.1.2. PRODUCT PORTFOLIO
      • 10.2.1.3. SCOT ANALYSIS
    • 10.2.2. ALLOSOURCE
      • 10.2.2.1. COMPANY OVERVIEW
      • 10.2.2.2. PRODUCT PORTFOLIO
      • 10.2.2.3. SCOT ANALYSIS
      • 10.2.2.4. STRATEGIC INITIATIVE
    • 10.2.3. AMEDICA CORPORATION
      • 10.2.3.1. COMPANY OVERVIEW
      • 10.2.3.2. PRODUCT PORTFOLIO
      • 10.2.3.3. SCOT ANALYSIS
      • 10.2.3.4. STRATEGIC INITIATIVES
    • 10.2.4. BAXTER INTERNATIONAL INC.
      • 10.2.4.1. MARKET OVERVIEW
      • 10.2.4.2. PRODUCT PORTFOLIO
      • 10.2.4.3. SCOT ANALYSIS
      • 10.2.4.4. STRATEGIC INITIATIVES
    • 10.2.5. CONMED CORPORATION
      • 10.2.5.1. COMPANY OVERVIEW
      • 10.2.5.2. PRODUCT PORTFOLIO
    • 10.2.6. DEPUY INC. (ACQUIRED BY JOHNSON AND JOHNSON)
      • 10.2.6.1. COMPANY OVERVIEW
      • 10.2.6.2. PRODUCT PORTFOLIO
      • 10.2.6.3. SCOT ANALYSIS
      • 10.2.6.4. STRATEGIC INITIATIVES
    • 10.2.7. EXACTECH INC.
      • 10.2.7.1. COMPANY OVERVIEW
      • 10.2.7.2. PRODUCT PORTFOLIO
      • 10.2.7.3. STRATEGIC INITIATIVES
    • 10.2.8. INTEGRA LIFESCIENCES HOLDING CORPORATION
      • 10.2.8.1. COMPANY OVERVIEW
      • 10.2.8.2. PRODUCT PORTFOLIO
      • 10.2.8.3. SCOT ANALYSIS
      • 10.2.8.4. STRATEGIC INITIATIVES
    • 10.2.9. MEDTRONIC INC.
      • 10.2.9.1. COMPANY OVERVIEW
      • 10.2.9.2. PRODUCT PORTFOLIO
      • 10.2.9.3. STRATEGIC INITIATIVES
    • 10.2.10. NUVASIVE INC.
      • 10.2.10.1. COMPANY OVERVIEW
      • 10.2.10.2. PRODUCT PORTFOLIO
      • 10.2.10.3. SCOT ANALYSIS
      • 10.2.10.4. STRATEGIC INITIATIVES
    • 10.2.11. RTI SURGICAL
      • 10.2.11.1. COMPANY OVERVIEW
      • 10.2.11.2. PRODUCT PORTFOLIO
      • 10.2.11.3. SCOT ANALYSIS
      • 10.2.11.4. STRATEGIC INITIATIVES
    • 10.2.12. SANOFI
      • 10.2.12.1. COMPANY OVERVIEW
      • 10.2.12.2. PRODUCT PORTFOLIO
      • 10.2.12.3. SCOT ANALYSIS
      • 10.2.12.4. STRATEGIC INITIATIVES
    • 10.2.13. SMITH & NEPHEW PLC
      • 10.2.13.1. COMPANY OVERVIEW
      • 10.2.13.2. PRODUCT PORTFOLIO
      • 10.2.13.3. STRATEGIC INITIATIVES
    • 10.2.14. STRYKER CORPORATION
      • 10.2.14.1. COMPANY OVERVIEW
      • 10.2.14.2. PRODUCT PORTFOLIO
      • 10.2.14.3. STRATEGIC INITIATIVES
    • 10.2.15. ZIMMER BIOMET INC.
      • 10.2.15.1. COMPANY OVERVIEW
      • 10.2.15.2. PRODUCT PORTFOLIO
      • 10.2.15.3. SCOT ANALYSIS
      • 10.2.15.4. STRATEGIC INITIATIVES

LIST OF TABLES

  • TABLE 1 NORTH AMERICA ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • TABLE 2 OLDER POPULATION BY AGE GROUP( 1900 TO 2050)
  • TABLE 3 POST-SURGERY COMPLICATION
  • TABLE 4 NORTH AMERICA ORTHOBIOLOGICS MARKET BY END USER 2019-2027 ($ MILLION)
  • TABLE 5 NORTH AMERICA HOSPITALS MARKET 2019-2027 ($ MILLION)
  • TABLE 6 NORTH AMERICA ORTHOPEDIC CLINICS MARKET 2019-2027 ($ MILLION)
  • TABLE 7 NORTH AMERICA ORTHOBIOLOGICS MARKET BY PRODUCTS 2019-2027 ($ MILLION)
  • TABLE 8 NORTH AMERICA DEMINERALIZED BONE MATRIX (DBM) MARKET 2019-2027 ($ MILLION)
  • TABLE 9 NORTH AMERICA ALLOGRAFT MARKET 2019-2027 ($ MILLION)
  • TABLE 10 NORTH AMERICA BONE MORPHOGENETIC PROTEIN (BMP) MARKET 2019-2027 ($ MILLION)
  • TABLE 11 NORTH AMERICA VISCOSUPPLEMENTATION MARKET 2019-2027 ($ MILLION)
  • TABLE 12 NORTH AMERICA SYNTHETIC BONE SUBSTITUTES MARKET 2019-2027 ($ MILLION)
  • TABLE 13 NORTH AMERICA STEM CELL THERAPY MARKET 2019-2027 ($ MILLION)
  • TABLE 14 NORTH AMERICA OTHER PRODUCTS MARKET 2019-2027 ($ MILLION)
  • TABLE 15 NORTH AMERICA ORTHOBIOLOGICS MARKET BY APPLICATION 2019-2027 ($ MILLION)
  • TABLE 16 NORTH AMERICA SPINAL FUSION MARKET 2019-2027 ($ MILLION)
  • TABLE 17 NORTH AMERICA TRAUMA REPAIR MARKET 2019-2027 ($ MILLION)
  • TABLE 18 NORTH AMERICA RECONSTRUCTIVE SURGERY MARKET 2019-2027 ($ MILLION)
  • TABLE 19 NORTH AMERICA TENDON AND LIGAMENT MARKET 2019-2027 ($ MILLION)
  • TABLE 20 NORTH AMERICA OTHER APPLICATIONS MARKET 2019-2027 ($ MILLION)
  • TABLE 21 NORTH AMERICA ORTHOBIOLOGICS MARKET BY COUNTRY 2019-2027 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • FIGURE 2 INCREASING DEMAND OF MINIMAL INVASIVE TECHNOLOGIES 2010-2025 ($ MILLION)
  • FIGURE 3 NORTH AMERICA ORTHOBIOLOGICS MARKET SHARE BY END USER 2018 & 2027 (%)
  • FIGURE 4 NORTH AMERICA ORTHOBIOLOGICS MARKET BY HOSPITALS 2019-2027 ($ MILLION)
  • FIGURE 5 NORTH AMERICA ORTHOBIOLOGICS MARKET BY ORTHOPEDIC CLINICS 2019-2027 ($ MILLION)
  • FIGURE 6 NORTH AMERICA ORTHOBIOLOGICS MARKET SHARE BY PRODUCTS 2018 & 2027 (%)
  • FIGURE 7 NORTH AMERICA ORTHOBIOLOGICS MARKET BY DEMINERALIZED BONE MATRIX (DBM) 2019-2027 ($ MILLION)
  • FIGURE 8 NORTH AMERICA ORTHOBIOLOGICS MARKET BY ALLOGRAFT 2019-2027 ($ MILLION)
  • FIGURE 9 NORTH AMERICA ORTHOBIOLOGICS MARKET BY BONE MORPHOGENETIC PROTEIN (BMP) 2019-2027 ($ MILLION)
  • FIGURE 10 NORTH AMERICA ORTHOBIOLOGICS MARKET BY VISCOSUPPLEMENTATION 2019-2027 ($ MILLION)
  • FIGURE 11 NORTH AMERICA ORTHOBIOLOGICS MARKET BY SYNTHETIC BONE SUBSTITUTES 2019-2027 ($ MILLION)
  • FIGURE 12 NORTH AMERICA ORTHOBIOLOGICS MARKET BY STEM CELL THERAPY 2019-2027 ($ MILLION)
  • FIGURE 13 NORTH AMERICA ORTHOBIOLOGICS MARKET BY OTHER PRODUCTS 2019-2027 ($ MILLION)
  • FIGURE 14 NORTH AMERICA ORTHOBIOLOGICS MARKET SHARE BY APPLICATION 2018 & 2027 (%)
  • FIGURE 15 NORTH AMERICA ORTHOBIOLOGICS MARKET BY SPINAL FUSION 2019-2027 ($ MILLION)
  • FIGURE 16 NORTH AMERICA ORTHOBIOLOGICS MARKET BY TRAUMA REPAIR 2019-2027 ($ MILLION)
  • FIGURE 17 NORTH AMERICA ORTHOBIOLOGICS MARKET BY RECONSTRUCTIVE SURGERY 2019-2027 ($ MILLION)
  • FIGURE 18 NORTH AMERICA ORTHOBIOLOGICS MARKET BY TENDON AND LIGAMENT 2019-2027 ($ MILLION)
  • FIGURE 19 NORTH AMERICA ORTHOBIOLOGICS MARKET BY OTHER APPLICATIONS 2019-2027 ($ MILLION)
  • FIGURE 20 PORTER'S FIVE FORCE MODEL
  • FIGURE 21 NORTH AMERICA ORTHOBIOLOGICS MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
  • FIGURE 22 HEALTHCARE EXPENDITURE IN THE UNITED STATES 2014 & 2025 (% OF GDP)
  • FIGURE 23 THE UNITED STATES ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • FIGURE 24 CANADA ORTHOBIOLOGICS MARKET 2019-2027 ($ MILLION)
  • FIGURE 25 ORTHOBIOLOGICS COMPANY MARKET SHARE 2018 (% )
Back to Top